Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053384 | 0.81 | GRM5 (0.56) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL15520747 | 0.81 | GRM5 (0.56) | GRM5CYP11B2IRAK4CYP11B1MGLL | |
| SCHEMBL18307164 | 0.81 | GRM5 (0.56) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL2398608 | 0.81 | GRM5 (0.56) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL2669710 | 0.81 | GRM5 (0.40) | GRM5CYP11B2KDM4EATMCYP11B1 | |
| Hydrochloric Acid SCHEMBL23168041 | 0.80 | GRM5 (0.55) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL2459914 | 0.79 | GRM5 (0.53) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL21863669 | 0.79 | GRM5 (0.53) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL14820097 | 0.79 | GRM5 (0.53) | GRM5CYP11B2KDM4EATMIRAK4 | |
| SCHEMBL4547953 | 0.79 | GRM5 (0.53) | GRM5CYP11B2KDM4EATMIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078461-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-10391076-B2 | Anti-cancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LTD. (AU) | 2019-08-27 | — | — | US | disclosed |
| US-10292960-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2019-05-21 | — | — | US | disclosed |
| EP-3043791-B1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | PITNEY PHARMACEUTICALS PTY LTD (AU) | 2019-04-24 | — | — | EP | disclosed |
| US-20180207124-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2018-07-26 | — | — | US | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010019606-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009146358-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009112677-A2 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009080291-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | GRM5 4218/4885CYP11B2 1507/4885KDM4E 1644/4885 |
| US-10391076-B2 | Anti-cancer agent comprising aminoacetonitrile compound as active ingredient | RB1, CCNA1, CCNT1 | GRM5 3706/4885CYP11B2 2932/4885KDM4E 2673/4885 |
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRM5 887/4885CYP11B2 4635/4885KDM4E 1495/4885 |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRM5 887/4885CYP11B2 4635/4885KDM4E 1495/4885 |
| US-10292960-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | RB1, CCNA1, NAT1 | GRM5 3982/4885CYP11B2 2567/4885KDM4E 3029/4885 |
| US-20180207124-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | RB1, CCNA1, NAT1 | GRM5 3982/4885CYP11B2 2567/4885KDM4E 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.